⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AIM News
AIM ImmunoTech Inc.
Form 8-K
sec.gov
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
globenewswire.com
AIM
Form 8-K
sec.gov
AIM
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041
globenewswire.com
AIM
AiM Medical Robotics Awarded $2 Million National Cancer Institute Grant to Advance MRI-Guided Robotic Treatment of Brain Cancer
globenewswire.com
AIM
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039
globenewswire.com
AIM
JTC Team Releases Virtual Investor "Why Now" On-Demand Conference Featuring Nine Public Company CEOs
accessnewswire.com
AIM
AKTX
CNSP
DARE
NVNO
ERNA
GRI
MBRX
OTLK
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
globenewswire.com
AIM
AIM ImmunoTech CEO Highlights Biodefense and Military Force Protection in Newly Published ‘Breaking Defense’ Article
globenewswire.com
AIM